- Home
- RIGL vs EDD Comparison
RIGL vs EDD Comparison
Compare RIGL & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- EDD
- Stock Information
- Founded
- RIGL 1996
- EDD 2007
- Country
- RIGL United States
- EDD United States
- Employees
- RIGL N/A
- EDD N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- EDD Finance Companies
- Sector
- RIGL Health Care
- EDD Finance
- Exchange
- RIGL Nasdaq
- EDD Nasdaq
- Market Cap
- RIGL 335.5M
- EDD 329.4M
- IPO Year
- RIGL 2000
- EDD N/A
- Fundamental
- Price
- RIGL $38.85
- EDD $5.30
- Analyst Decision
- RIGL Buy
- EDD
- Analyst Count
- RIGL 5
- EDD 0
- Target Price
- RIGL $38.20
- EDD N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- EDD 254.3K
- Earning Date
- RIGL 08-05-2025
- EDD 01-01-0001
- Dividend Yield
- RIGL N/A
- EDD 7.52%
- EPS Growth
- RIGL N/A
- EDD N/A
- EPS
- RIGL 5.43
- EDD N/A
- Revenue
- RIGL $267,921,000.00
- EDD N/A
- Revenue This Year
- RIGL $59.93
- EDD N/A
- Revenue Next Year
- RIGL N/A
- EDD N/A
- P/E Ratio
- RIGL $7.15
- EDD N/A
- Revenue Growth
- RIGL 105.62
- EDD N/A
- 52 Week Low
- RIGL $12.66
- EDD $4.22
- 52 Week High
- RIGL $43.72
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- EDD 56.10
- Support Level
- RIGL $39.00
- EDD $5.24
- Resistance Level
- RIGL $42.08
- EDD $5.42
- Average True Range (ATR)
- RIGL 2.32
- EDD 0.05
- MACD
- RIGL -0.37
- EDD -0.01
- Stochastic Oscillator
- RIGL 53.26
- EDD 40.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.